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Abstract
Phaeochromocytoma and extra adrenal paraganglioma are rare neuroendocrine tumours and have the potential to
secrete adrenaline, noradrenaline and dopamine causing a myriad of clinical symptoms. Prompt diagnosis is essential
for clinicians and requires a multidisciplinary specialist approach for the clinical and laboratory investigation, diagnosis,
treatment and follow-up of patients. This paper is an integrated review of the clinical and laboratory evaluation and
treatment of patients suspected to have phaeochromocytoma or paraganglioma, highlighting recent developments and
best practices from recent published clinical guidelines.
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Introduction
Phaeochromocytomas are rare neuroendocrine
tumours that arise from sympathetic adrenomedullary
chromaﬃn tissue.1,2 These tumours usually produce
one or more catecholamines: noradrenaline (NAd),
adrenaline (Ad) and dopamine (DP). In contrast, para-
gangliomas are derived from extra-adrenal chromaﬃn
tissue of the paravertebral ganglia of abdomen, pelvis
and thorax. Diﬀerences in clinical features and behav-
iour suggest that they should be regarded as diﬀerent
diseases.3
Paragangliomas do not typically secrete Ad due to
the reduced expression peripherally of the cortisol-
dependant enzyme phenylethanolamine-N-methyl-
transferase, which converts NAd to Ad.4
Paragangliomas can also arise from parasympathetic
ganglia found along the glossopharyngeal and vagal
nerves in the neck, and base of the skull.2 The latter
are usually biochemically silent.
Phaeochromocytomas account for approximately
85%, and sympathetic and parasympathetic
paragangliomas 15–20%, of chromaﬃn cell tumours.5
For simplicity, throughout this article phaeochromocy-
tomas and paragangliomas will be referred to as PPGL.
The prevalence of PPGL varies according to the
population studied. In an outpatient hypertensive
population, the prevalence is reported as 0.2–0.6%.6–9
Autopsy studies show that 0.05–0.1% of patients have
undiagnosed tumours.10–12 It has been suggested that
the prevalence of the latter is falling as more PPGL are
1Department of Clinical Biochemistry and Metabolic Medicine, Royal
Liverpool and Broadgreen University Hospitals Trust, Liverpool, UK
2Manchester Academic Health Science Centre, University of Manchester,
Manchester, UK
3Department of Cellular Pathology, Royal Liverpool and Broadgreen
University Hospitals Trust, Liverpool, UK
4Department of Endocrine Surgery, Royal Liverpool and Broadgreen
University Hospitals Trust, Liverpool, UK
Corresponding author:
Andrew S Davison, Royal Liverpool University Hospital, 4th Floor
Duncan Building, Prescot Street, Liverpool L7 8XP, UK.
Email: andrew.davison@RLBUHT.nhs.uk
Annals of Clinical Biochemistry
0(0) 1–15
! The Author(s) 2017
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/0004563217739931
journals.sagepub.com/home/acb
being picked up, while people are alive owing to better
screening tests and more incidental ﬁndings during ima-
ging for other reasons. It is estimated that 1.5–14.0% of
incidentally discovered adrenal masses found on com-
puterized tomography (CT) or magnetic resonance
imaging (MRI) are phaeochromocytomas.13–15
The most common indications for biochemical
screening for PPGL are: (a) the presence of both hyper-
tension and episodic symptoms of catecholamine excess
(e.g. palpitations, headache and periods of diaphoresis);
(b) treatment of resistant hypertension; (c) assessment
of functionality of incidentally identiﬁed adrenal
masses; (d) predisposition to hereditary PPGL and (e)
assessment of recurrence of PPGL.
Clinical presentation
PPGL are notoriously diﬃcult to diagnose, especially
for the non-specialist clinician as they are rare in the
community. Most clinicians never see a patient with a
PPGL, and the symptoms can be mixed and if not
clearly analysed are similar to those of many diseases,
including anxiety attacks. Moreover, unless the diagno-
sis is considered, it cannot be reached. Symptoms vary
according to which catecholamine is being secreted, and
therefore which a- and/or b-receptor(s) are being stimu-
lated. Only 30–40% of patients demonstrate the classic
triad of headache, palpitations and diaphoresis asso-
ciated with functional PPGL.16,17 In many patients,
hypertension will be associated with these symptoms.
Patients may have been diagnosed with hypertension
previously and treated with polypharmacy due to the
resistance of the hypertension. This group of patients
along with young hypertensive patients (<40 years old)
should be screened for causes of secondary hyperten-
sion, including PPGL. Catecholamine secretion can be
episodic or continuous; this variable symptomatology
contributes to the diﬃculty in making the diagnosis.
Resistant or labile hypertension
Hypertension is present in 70–80% of patients with
PPGL.16,17 It may be described as labile or paroxysmal
(37%) but is often persistent hypertension (63%).17
Persistent hypertension is more usual with a predomin-
ant NAd-producing tumour, whereas Ad is associated
with orthostatic and paroxysmal hypertension.18 Labile
hypertension can cause diﬃculties in treatment, result-
ing in the trial of many diﬀerent antihypertensive drugs
at diﬀerent dosages. This trial of diﬀerent agents with-
out success should raise the suspicion of the potential
presence of PPGL. When hypertension appears resist-
ant to single therapy, one should be suspicious of a
possible PPGL. This tends to be more prevalent in
the young hypertensive population, and while PPGL
only accounts for a small percentage (2–4%) of these
patients,19,20 it is curable and so should be screened for.
Normotensive patients
Although frequently associated with hypertension, 5–
55% of patients will be normotensive.16,17,21 Due to
this, they may be incidentally discovered or go undiag-
nosed without the paroxysmal nature of the hyperten-
sion or the presence of orthostatic hypotension on
standing. Lower concentrations of catecholamines may
be seen more in normotensive PPGL patients than in
those who are hypertensive. While it makes sense that
the extent of symptoms is related to the concentration of
catecholamines produced, this does not necessarily cor-
respond to size of the tumour on imaging.17
Palpitations/cardiac events
Palpitations (runs of tachycardia sometimes associated
with anxiety but, in the absence of a causative stressful
event) may result from PPGL. In such situations, the
symptoms may be mistakenly attributed to anxiety22 or
a stress response provoked by a particular event.
Palpitations usually result from the stimulus of
b1-receptors. PPGL can also present with cardiomyo-
pathies, pulmonary oedema and cardiac arrests.23
Sweating and pallor
Stimulation of the a1-receptor causes sweating and is
seen in a number of patients with PPGL.
A typical loss of colour or pallor is seen in PPGL
patients, where they are described as going ‘white’ due
to vasoconstriction caused by a1-receptor stimulation.
Vasoconstriction can also be peripheral. This can be
observed when the a1-receptors are blocked in prepar-
ation for surgery, when often there is a visible change in
skin colour and temperature.
Headache
Headaches are often precipitated by the increase in blood
pressure and vasodilation and are more common in hyper-
tensive PPGL patients than in normotensive patients.17
Abdominal pain
Abdominal pain can be an associated symptom of PPGL
in a stressful event, precipitating an acute crisis.24
Hyperglycaemia
Diabetic ketoacidosis, type 2 diabetes and hypergly-
caemic crisis have been reported as a presenting feature
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of PPGL, especially when there are atypical features
such as labile hypertension or a patient’s failure to
respond to insulin therapy.25,26
Catecholamines normally prevent hypoglycaemia by
promoting lipolysis, gluconeogenesis and glycogenoly-
sis through stimulation of b2-receptors and are a cause
of insulin resistance. The excess uncontrolled secretion
of catecholamines from a PPGL can therefore result in
hyperglycaemia. Elective surgical treatment can lead to
a reduction in dose of diabetic medication or even cure
the patient’s ‘diabetes’.27
Unusual symptoms
As there are numerous eﬀects resulting from a- and
b-receptor stimulation, PPGL can less commonly pre-
sent with symptoms including hypercalcaemia and
hypercortisolaemia28 due to the increased secretion of
ACTH and thromboembolic events.29,30
Phaeochromocytoma crisis
PPGL crisis is deﬁned as an acute severe presentation
of a catecholamine-induced haemodynamic instability
causing end-organ damage or dysfunction.31 It can be
divided into types A and B. Type A represents a limited
crisis with haemodynamic instability and end-organ
dysfunction or damage of one or more organs. Type
A can progress to type B, which is an extensive crisis
with the patient going into shock. Type B crisis is char-
acterized by sustained hypotension and multiorgan
damage of two or more systems.32 This diagnosis can
be confused with myocardial infarction, septic shock
and cardiomyopathy.30
A crisis can be precipitated by many factors includ-
ing a general anaesthetic in an unprepared patient,
direct trauma to the tumour, drugs including metaclo-
pramide and some contrast agents. Type A crisis carries
a 6% mortality, while type B confers a higher mortality
of 28%.32
Investigation
Biochemical screening
Recent clinical practice guidelines1 for the diagnosis of
PPGL state that total fractionated urine metadrena-
lines (UMets) or plasma-free metadrenalines (PMets)
should be used as an initial biochemical screen for
PPGL. The purported advantages and disadvantages
of plasma and urine metadrenalines are summarized
in Table 1 (adapted from reference).33
Several studies have demonstrated that plasma and
urinary O-methylated catecholamine metabolites, nor-
metadrenaline (NMA) and metadrenaline (MA) have
high diagnostic sensitivity and speciﬁcity, which is
essential for the biochemical diagnosis of PPGL
(Table 2).34–53
While there have been diﬀerences observed in the
diagnostic sensitivity and speciﬁcity of UMets and
PMets using diﬀerent analytical methodologies, to
date, there has not been a multicentre comparison
using the gold standard method1 of liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS) for
analysis.
Measurement of 3-methoxytyramine (3-MT) is not
recommended for the investigation of PPGL, but it has
the potential to distinguish patients with and without
metastases and may be useful in identifying patients
with inherited forms of PPGL.54–56
3-MT is a diagnostically more sensitive biomarker of
tumoural DP production than plasma or urinary DP in
patients with mutations in the succinate dehydrogenase
type B (SDHB) gene.54–56
The greatest challenge associated with the interpret-
ation of UMets and PMets results is the ‘borderline-
positive reference range’ in patient populations with a
low prevalence of PPGL.
In such cases, a false-positive result (increase
of PMets and or UMets in the absence of a tumour)
due to a confounding factor such as concomitant
drug therapy or a physiological increase in catechol-
amine release is more likely than true-positive result
(increase in UMets and or PMets due to the presence
of a tumour) (Table 3). Borderline increases in PMets
or UMets have been deﬁned as anything between
one and three times the upper limit of the reference
interval.5
Deﬁning the pretest probability of a PPGL in an
individual patient is essential to the appropriate inter-
pretation of results, which should not solely be
based on the magnitude of the increase above the ref-
erence range.5
Assurance when one evaluates the importance of a
borderline result can be gained by collecting a repeat
plasma or urine sample under standardized low-stress
conditions, for example, collecting a fasting plasma
sample in the supine position after 20min rest and
avoiding urine collections after exercise.1 Darr et al.49
recently reported that the collection of a plasma sample
in a non-fasting ambulant population can give false-
positive rates of up to 30% compared with a 5%
false-positive rate in patients, where the samples were
collected under supine and fasted conditions.
In contrast, Boote et al.52 reported in a small study
that diagnostic sensitivity and speciﬁcity were accept-
able for PMets when a sample was collected in a seated
position for detection of PPGL. However, it is the
authors’ view that where practicable samples should
be collected after fasting in the supine position.
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Additional reassurance can be achieved by demon-
strating similar patterns of NMA and MA in the
plasma and urine, thus it is the authors’ recommenda-
tion in such situations that paired samples are collected.
Moreover, patients should have any medication that
may cause an analytical interference or result in a
pharmacological increase in MAs (Table 3) modiﬁed
and/or any underlying conditions managed optimally
before re-testing.57–72
Genetic evaluation
It is estimated that 30–40% of PPGL73,74 have a genetic
predisposition which can be found in one of at least 14
genes and resonate from a variety of functional classes
(Table 4).73–94
Mutations discovered to date cluster into two
groups. Cluster one mutations encompass genes that
are involved with the activation of the hypoxic response
via speciﬁc transcription factors known as hypoxia-
inducible factors (HIFs). Mutations in the genes
responsible for regulation of these transcription factors
can result in HIF pathways becoming constitutively
active, leading to pseudohypoxic conditions that
result in cell proliferation and angiogenesis.73,74
Cluster 2 mutations aﬀect genes that are involved
with kinase signalling pathways (notably MAPK
and mTOR pathways). This leads to the activation of
downstream targets that promote cell proliferation and
survival.75–78
Genetic testing is relatively expensive; therefore, only
the most likely mutations are tested for in a given
patient. The decision on which mutations to test for is
guided by clinical presentation, biochemical testing and
imaging. The clinical presentation of type-1 neuroﬁbro-
matosis (NF-1) is usually apparent so that genetic
Table 2. Diagnostic performance characteristics of plasma and urine metadrenalines.
Analytical
method
Sampling position
(refers to plasma
assay only)
Plasma Urine(24-h collection)
Reference
Diagnostic
sensitivity
Diagnostic
specificity
Diagnostic
sensitivity
Diagnostic
specificity
LC-ECD Supine 99 89 97 69 34
LC-ECD Seated 97 85 35
RIA Seated 96 79 93 80 36
LC-ECD Not stated 95 95 37
LC-ECD Supine 100 97 38
EIA Supine 97 86 39
LC-ECD Not stated 100 98 86 95 40
EIA Not stated 80 100 41
LC-ECD Supine 96 89 95 86 42
LC-MS/MS Seated 100 96 43
EIA Seated 95 95 43
EIA Seated 100 88 44
LC-MS/MS Seated 100 95 44
EIA Seated 94 94 45
EIA Seated 91 99 46
EIA Seated 89 90 93 78 47
EIA Supine 96 97 89 95 48
LC-MS/MS Seated 76 98 95 80 49
LC-MS/MS Supine 94 97 49
EIA Supine 96 95 50
LC-MS/MS Supine 98 100 50
LC-MS/MS Seated 96 76 96 94 51
LC-MS/MS Seated 93 90 52
LC-MS/MS Supine 100 75 53
Note: Data from studies published between 2002 and 2017. The performance characteristics vary according to cut-off used for
metadrenalines.
LC-ECD: liquid chromatography-electrochemical detection; RIA: radioimmunoassay; EIA: enzyme immunoassay; LC-MS/MS:
liquid chromatography tandem mass spectrometry.
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testing in not usually required.79 Conversely, mutations
in the SDHx gene can have major implications on prog-
nosis so that knowledge of the speciﬁc mutation is
important. The subunit SDHB is known to have a
high likelihood of malignancy unlike mutations in
SDHA, SDHC, SDHD and SDHAF2 sub-
units.76,77,83,85,86 However, with the increasing use and
availability of next generation sequencing, the
approach to genetic evaluation of patients with PPGL
is likely to change from a less targeted approach look-
ing for known mutations to one that will screen entire
genes identifying both novel and known mutations.
The identiﬁcation and understanding of the role of
speciﬁc genetic mutations that predispose patients to
PPGL increase the potential for the development of
‘personalized medicine’. An example of this is the muta-
tions that have been identiﬁed in the rearranged during
transfection (RET) gene. This gene is responsible for
the multiple endocrine neoplasia 2 (MEN-2) phenotype
and its mutations are grouped into one of four levels
(A–D), with patients carrying level D mutations having
the greatest likelihood of developing medullary thyroid
carcinoma (MTC).73
Syndromes associated with PPGL
MEN-2
MEN-2 is an autosomal dominant syndrome with RET
proto-oncogene mutations associated with MTC,
PPGL and hyperparathyroidism.95 PPGL has a vari-
able penetrance, depending on the familial kindred.
Fifty per cent of patients with a mutation in RET will
develop a PPGL at some point in their lives.96 In only
25% of cases will it be the presenting disease, explain-
ing why patients need to be screened lifelong for PPGL
and certainly before any surgery. MTC carries almost
100% penetrance in these syndromes and can occur in
patients under the age of ﬁve years depending on the
codon aﬀected.97
Table 3. Analytical and pharmacological factors responsible for potential interferences in the measurement and interpretation of
metadrenalines.
Agent causing increase
in plasma or urine
metadrenalines Cause of increase
Plasma Urine
ReferencesNMA MA 3-MT NMA MA 3-MT
Phenoxybenzamine Pharmacological Y Y 57
Amitriptyline, venlafaxine Pharmacological Y Y 57,58
Moclobemide, phenelzine Pharmacological Y Y Y 57
Amphetamines, ephedrine, cocaine Pharmacological Y Y Y Y 57
L-DOPA Pharmacological Y Y 59
Banana, pineapple, shelled walnuts Pharmacological Y Y Y 60
Coffee, nicotine Pharmacological Y Y 34
Curry leaves (methoxyhydroxybenzylamine) Analyticala Y Y 61
Buspirone Analyticala Y 62
Paracetamol Analyticala Y Y Y Y 63,64
Sulphasalazine Analyticala Y Y 65
Mesalamine Analyticala Y 66
Methenamine Analyticala Y Y 67
Amoxicillin Analyticala Y 68
L-DOPA Analyticala Y Y Y Y Y Y 69
L-DOPA Analyticalb Y Y 70
Isoproterenol Analyticalb Y 71
MDMA Analyticalb Y 71
HMMA Analyticalb Y 72
Isoetharine Analyticalb Y 71
MDA Analyticalb Y 71
NMA: normetadrenaline; MA: metadrenaline; 3-MT: 3-methoxytyramine; MDMA: 3,4-methylenedioxymethamphetamine; MDA: 3,4-methylenediox-
yamphetamine; HMMA: 4-hydroxy-3-methoxymethamphetamine.
aLiquid chromatography-electrochemical detection method.
bLiquid chromatography tandem mass spectrometry method.
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Succinyl dehydrogenase syndrome
The SDHx family of nuclear genes (SDHA, SDHB,
SDHC, SDHD) encodes for the subunits of the mito-
chondrial enzyme SDH. A ﬁfth nuclear gene (SDHAF2
or SDH5) encodes a protein required for ﬂavination of
SDHA. Mutations in these genes are inherited in an
autosomal-dominant manner and cause the develop-
ment of single or multiple PPGL in the head and
neck, mediastinum, abdomen and pelvis. The site of
PPGL (dictated by the gene abnormality) indicates
the likelihood of secretion and malignancy risk (34–
97% in SDHB).1,98
Patients should be genetically screened for SDHx
abnormalities in the case of head and neck paraganglio-
mas, multiple PPGL (synchronous or metachronous),
recurrent disease and early onset of PPGL (<45
years).1,99
Von Hipple–Lindau
Von Hipple–Lindau (VHL) is inherited in an autoso-
mal-dominant manner in 80% of cases and is charac-
terized by multiple vascular tumours in the eyes, brain
and nervous system with benign and malignant
Table 4. Genes known to play a role in the development of PPGL (both hereditary and somatic) including associated syndromes and
clinical and biochemical presentations.
Gene Inheritance
Risk of
malignancy Syndrome Features References
VHLa Hereditary Low Von Hippel–Lindau RCC, retinal haemangioblas-
tomas, pancreatic
tumours, endolymphatic
tumours, epididymal cysts
76,77
SDHAa Hereditary Unknown – GIST 76,77,83,85,86
SDHBa Hereditary High Paraganglioma type 4 GIST and RCC 76,77,83,85–86
SDHCa Hereditary Low Paraganglioma type 3 GIST and RCC 76,77,83,85,86
SDHDa Hereditary Low Paraganglioma type 1 GIST, pituitary adenomas and
RCC
76,77,83,85,86
SDHAF2a Hereditary Unknown Paraganglioma type 2 Head and neck paraganglioma 75,76,84
HIF2A (EPAS1)a Somatic Unknown Polycythaemia para-
ganglioma syndrome
Polycythaemia and
somatostatinomas
80–82
FHa Hereditary Unknown Reed syndrome RCC, smooth muscle
tumours in the skin and
uterus
87
RETb Hereditary and
somatic
Low Multiple endocrine
neoplasia type 2
MTC, hyperparathyroidism,
cutaneous lichen amyloid-
osis and marfanoid habitus
76,77
Neurofibrominb Hereditary and
somatic
Moderate Neurofibromatosis
type 1
‘Cafe au lait’ spots, multiple
fibromas, optic pathway
and brainstem gliomas,
astrocytomas, soft tissue
sarcomas
77,79
MAXb Hereditary and
somatic
Low – Mainly PPGL 78,89
TMEM127b Hereditary Low – RCC, PCC 88,90,91
KIF1B Hereditary Unknown – Neuroblastoma, medulloblas-
toma, ganglioneuroma,
leiomyosarcoma and lung
adenocarcinoma
93–95
HRAS Somatic Unknown – None reported 92
FH: fumarate hydratase; GISTs: gastrointestinal stromal tumours; HIF2: hypoxia-inducible factor 2; MAX: MYC-associated factor X; MTC: medullary
thyroid carcinoma; RCC: renal cell carcinoma; MTC: medullary thyroid cancer; SDH: succinate dehydrogenase; TMEM127: transmembrane protein 127;
VHL: von Hippel–lindau; RET: rearranged during transfection.
aCluster 1 mutation.
bCluster 2 mutation.
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tumours in sympathetic ganglia, kidneys, pancreas and
adrenal glands. The VHL gene is a tumour suppressor
gene. VHL is divided into subtypes depending on the
risk of PPGL and renal cell carcinoma.100,101 Type 2
(A, B and C), characterized by missense mutations, is
all high risk for PPGL. Prevalence of PPGL in this
syndrome is 10–25%.102 Mean age at diagnosis of
PPGL in VHL is 30 years old.103 Suggested VHL sur-
veillance advises screening for PPGL from ﬁve years
old.101 Up to 20% of all PPGL are secondary to
VHL, reinforcing the argument for genetic screening
in young patients.
Neurofibromatosis type 1 (NF-1)
NF-1 is an uncommon autosomal-dominant disease
that has a low risk (<1–2.9%) of PPGL.104 However,
PPGL can occur in the very young and there may be a
higher risk of malignancy (7–12%).104,105 Genetic
screening for PPGL in neuroﬁbromatosis is not rou-
tinely performed, but the diagnosis should be con-
sidered in NF-1 patients with hypertension.
Takotsubo syndrome
Takotsubo syndrome is an acute cardiac entity charac-
terized by a left ventricular wall motion abnormality
with a circumferential extension beyond that expected
from the coronary artery supply and resulting in left
ventricular ballooning during systole. PPGL can be
the causative stress.106 In 80 reported cases, men con-
stituted a higher proportion (30%) of PPGL-induced
Takotsubo syndrome as compared with all cases
(4.5%). Also patients with PPGL were signiﬁcantly
younger (19.8 years).107 Patients present frequently
with cardiac symptoms, including chest pain, palpita-
tions and dyspnoea, but abdominal pain can be a warn-
ing symptom in these patients.
Imaging
Imaging is an important part of diagnosis and treat-
ment planning for patients with PPGL. Imaging may
be anatomical (important for surgical planning) or
functional to assess sites of possible metastases and to
evaluate possible treatment options in surgically unre-
sectable or extensive disease.
Anatomical imaging
CT
Abdominal CT is often how PPGL are incidentally
diagnosed. PPGL are thought to account for about
1.5–14% of adrenal incidentalomas.13–15 CT is a good
method of the assessment of adrenal incidentalomas as
benign adrenal cortical neoplasms will usually be fat
ﬁlled and therefore have Hounsﬁeld units (HUs) of
<10 (with no contrast). Unfortunately, many CTs are
performed with intravenous contrast, which makes the
HU an unreliable assessment. CT can also be used to
assess the absolute and relative washout of an adrenal
lesion. An absolute percentage washout of greater than
60% or a relative percentage washout of over 40% indi-
cates a benign lesion. PPGL do not typically have a
benign appearance on CT with HU >10, and often
appear suspicious and may be reported as malignant
due to their heterogenous appearances due to their
hypervascularity and central necrosis. However, com-
bined with abnormal MAs, these indeterminate or sus-
picious features can be diagnosed as a PPGL. A CT
may suggest malignancy based on gross invasion into
other glands and vascular structures or the presence of
abdominal metastases.
MRI
MRI may be used to further deﬁne the characteristics
of an indeterminate adrenal lesion on CT. Typically, a
PPGL will light up with a hyperintense ‘bright white’
signal in T2-weighted images. MRI is also used for
follow-up for SDHx families to prevent the excess radi-
ation exposure associated with whole body CT.
Functional imaging
Metaiodobenzylguanidine scintigraphy
Metaiodobenzylguanidine (MIBG) is an analogue of
NAd and accumulates in the neurosecretory granules.
It is combined with 123iodine to visualize on single-
photon emission computed tomography (SPECT) ima-
ging or fused with SPECT-CT for improved anatomical
information. Speciﬁcities for phaeochromocytoma
range from 70 to 100% and 84 to 100% for paragan-
gliomas, with sensitivities of 85–88% and 56–76%,
respectively.108 To aid diﬀerentiation of pathological
from physiological uptake, a tumour/liver ratio may
be used, as diﬃculties can arise with increased physio-
logical uptake and in small tumours. There is a ques-
tion whether all PPGL patients need an MIBG, but the
authors’ unit still uses MIBG to assess for metastases
and conﬁrm localization. MIBG is more sensitive if
performed while not on a-blockade.
Positron emission tomography computerized
tomography
PPGL express somatostatin receptors and can be
detected by somatostatin analogues when using
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positron emission tomography computerized tomog-
raphy (PET-CT). While traditionally octreotide scintig-
raphy has been the second-line functional imaging after
MIBG, more recently, dotanoc/dototate has been used.
Dotanoc has an increased sensitivity to a greater
number of somatostatin receptors than octreotide.109
68Gallium dotanoc PET-CT has a sensitivity of 80–
96%, speciﬁcity of 85% and 100% accuracy for malig-
nant PPGL and corresponding metastases.109–111 These
recent studies appear to show improved sensitivity com-
pared with [18F]-ﬂuorodeoxyglucose (FDG) PET. This
also opens the possibility of dotatate therapy in meta-
static disease.
FDG PET-CT
[18F]-FDG PET-CT relies on increased glucose metab-
olism in malignancy. While proven in many cancers, the
role in PPGL is not clear. Studies have not clearly
demonstrated a role for signiﬁcantly diﬀerentiating
between benign and malignant PPGL; there does, how-
ever, appear to be some evidence showing increased
standardized uptake value max scores for PPGL in
the SDHx syndromes112 and in MIBG-negative
PPGL patients. However, more recent data would sug-
gest that 68gallium dotanoc PET-CT has a higher sen-
sitivity and increased sensitivity for individual
metastatic lesions than [18F]-FDG PET-CT.111
Treatment
Treatment of PPGL relies on the expertise of endocrin-
ologists, surgeons and anaesthetists. When performed
within specialist teams and high volume units, these can
be well controlled and safe operations. Surgery on
unprepared patients with incidental PPGL can cause
a crisis, resulting in signiﬁcant hypertension, arrhyth-
mias, stroke or death. The treatment of PPGL can be
divided into medical, surgical and adjuvant treatment
in malignancy. The treatment of a PPGL crisis is med-
ical and supportive treatment of organ failure.
Medical treatment
Alpha-adrenergic receptor blockade is the main-
stay of medical treatment for PPGL. Typically,
phenoxybenzamine has been the agent of choice as a
non-competitive and non-selective alpha-receptor
antagonist. However, doxazosin can be used as a com-
petitive, short-acting selective a1 receptor blocker.
113
There is some evidence that doxazosin may cause
less postoperative hypotension.114 Li et al.114 demon-
strated less intra- and postoperative variability in blood
pressure with doxazosin compared with
phenoxybenzamine.
During a-blockade, it is important that ﬂuid balance
is monitored to ensure that the vasodilation produced is
being supported by adequate ﬂuid intake. This is usu-
ally adequate orally, but is often supplemented by
an intravenous infusion of crystalloid ﬂuid the night
before surgery. Once the a-blockade is complete
with a satisfactory postural blood pressure drop of
20–40mmHg, a reﬂex tachycardia may develop, and
at this point, it is safe to introduce a b-blocker to
reduce the risk of tachycardias and arrhythmias.
However, the patient should be a-blocked before the
introduction of a b-blocker. Alpha-blockers can also
be given intravenously, for example phentolamine can
be used in a PPGL crisis or immediately periopera-
tively. Calcium channel blockers can also be used,
although less commonly.
Surgical treatment
Abdominal PPGL can be removed by an open adrena-
lectomy if large or malignant, laparoscopic adrenalect-
omy or retroperitoneoscopic (through the back)
adrenalectomy for smaller lesions (usually <4 cm). A
predominantly no touch technique is important, as pres-
sure on the lesion causes a spike in secretion of catechol-
amine. Any PPGL surgery carries additional increased
risks of stroke, myocardial infarction and death as com-
pared with normal adrenal surgery due to the extremes
of hypo- and hypertension that can occur in surgery
despite a- and b-blockades. It is therefore essential that
these operations are performed in specialist centres. If
the lesion is suspicious of a malignant PPGL, then it is
important to achieve clear margins in the surgical resec-
tion, and this may mean resection of surrounding struc-
tures if invaded by the tumour.
Postsurgical therapy
Routinely, no adjuvant therapy is required for a benign
PPGL. The diﬃculty is predicting and deﬁning malig-
nancy in these tumours. Paragangliomas have a higher
risk of being malignant than phaeochromocytoma.
Surveillance imaging, the recurrence of symptoms or
biochemically positive results, may reveal metastases
or local recurrence and therefore conﬁrm malignancy.
Malignant tumours are rare and therefore adjuvant
treatment is not well characterized. Adjuvant treatment
is usually only employed when metastases are present
and often requires a multimodal approach. The ﬁve-
year survival rate for patients with metastatic disease
is around 50%.5 Review of a cohort of 90 patients in
France with malignant PPGL assessed the natural his-
tory of PPGL and showed a progression-free survival
of 46% at one year indicating that active surveillance of
disease progression is a valid option,115 especially when
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treatment options are limited. Malignant PPGL that
are MIBG negative have a particularly poor prognosis;
treatment options for these patients are poorly deﬁned.
MIBG therapy
PPGL tumours and metastases that are positive on
imaging for 123I-MIBG can be treated with MIBG ther-
apy in the form of 131I-MIBG, which emits beta radi-
ation. A number of studies have been published on this
topic, but are not comparable due to study design
making it diﬃcult to draw reliable conclusions on the
impact of 131I-MIBG therapy. Yoshinaga et al.116 pro-
spectively recruited patients with metastatic neuroendo-
crine tumours for MIBG therapy. Forty-eight patients
had malignant PPGL. Forty-ﬁve (94%) had previous
treatment including surgery (79%), chemotherapy
(50%) or standard radiotherapy (23%). Fifty-seven
per cent of the patients received repeated MIBG ther-
apy. Of the PPGL patients, 86% showed partial remis-
sion or stable disease by RECIST tumour size criteria:
one partial regression, 54 stable disease and 10 progres-
sive disease. In this study, no signiﬁcant changes were
seen in blood pressure at the ﬁrst follow-up, but at the
last follow-up, a signiﬁcant reduction in systolic blood
pressure was seen. Rutherford et al.117 performed a
retrospective review of 22 patients with PPGL assessed
by World Health Organization (WHO) response cri-
teria for symptomatic response, hormonal response
and tumour size response. The patients were treated
with surgery (86%), chemotherapy (32%) and radio-
therapy (4%).
Nineteen per cent of patients showed complete or
partial radiological response with 59% showing stable
disease at six months. This study also demonstrated an
improvement in hormone secretion and symptoms, but
these factors had no signiﬁcant eﬀect on survival. A 68%
ﬁve-year overall survival was seen in this study with a
median survival of 17 years. A phase 2 prospective study
showed 22% complete response or partial remission and
35% showed progressive disease at one year. Overall
ﬁve-year survival was 64% with higher doses of
MIBG.118 Toxicity and side-eﬀects of MIBG therapy
can be signiﬁcant and dose dependent. Side-eﬀects are
seen in 47–54% and include nausea, hypertension,
abdominal pain, neutropaenia, hypothyroidism, ovarian
failure and bone marrow suppression.116–118 Dotanoc
therapy with 90yttrium-dotanoc and 177lutetium-dotanoc
can also be used for therapy based on uptake and success
in neuroendocrine tumours.
Chemotherapy
Chemotherapy regimens that have been used for pallia-
tive chemotherapy include CVD (cyclophosphamide,
vincristine and decarbazine) which gave a median pro-
gression-free survival of 5.4 months (2–26 months)119
and on systematic review also reduced catecholamine
secretion in 56% in combination therapy.120
Temozolomide has been used as a single agent chemo-
therapy and associated with a tumour response and pro-
gression-free survival of 13.3 months in patients with
SDHB mutations.121 Chemotherapy is often used with
other therapies and therefore it can be diﬃcult to attri-
bute which therapy is producing the eﬀect. Many
patients actually die from catecholamine excess, and
hence the reduction in catecholamines is a signiﬁcant
beneﬁt but combination with a-blockers and b-blockers
will be required with a heavy tumour load and secretion.
Molecular-targeted therapy
Sunitinib is a tyrosine kinase inhibitor that is an eﬀect-
ive antiangiogenic agent that targets vascular endothe-
lial growth factor receptors 1 and 2 that are
overexpressed in some metastatic PPGL.122
Progression-free survival is similar to that achieved
using chemotherapy at 4.1 months.123 The PI3K/Akt/
mTOR pathway is thought to be involved in the patho-
genesis of metastatic PPGL. mTOR inhibitors have
been shown to have antitumour eﬀects on PPGL cells
in animal models.124 Trials are underway to further
investigate the clinical applications.
Histological evaluation
Macroscopic features
Phaeochromocytoma are soft, encapsulated tumours
with a yellow/brown to red cut surface (Figure 1(a))
and may weigh from just a few grams to up to 4 kg.
Larger tumours can show areas of necrosis, cystic
degeneration or haemorrhage. They usually have a
thin rim of compressed adrenal cortex peripherally. If
potassium dichromate is added to fresh tumour, it will
turn dark brown (chromaﬃn reaction).
Microscopic features
Microscopically, the tumour cells have round to oval
nuclei with a prominent nucleolus and may contain
cytoplasmic inclusions. The cells have a ﬁnely granular
basophilic or amphophilic cytoplasm and are usually
arranged in nests (Zellballen pattern) surrounded by a
rich vascular network (Figure 1(b)). Marked nuclear
pleomorphism and hyperchromasia can be seen
(Figure 1(c)), but similar to capsular and vascular inva-
sion, this in itself is not a reliable indicator of malig-
nancy. Mitoses are rarely found. Occasionally, the
tumour cells may have an oncocytic appearance due
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to the presence of large numbers of mitochondria.
Other features include ganglion-like cells, dys-
trophic calciﬁcation and melanin pigment,125 and the
presence of amyloid.126 The nests are outlined by
sustentacular cells, which provide structural support
and are not visible with routine staining techniques,
but can be highlighted with S-100 immunocytochem-
istry (Figure 1(d)).
PPGL can be associated with other tumours of the
adrenal medulla, such as ganglioneuroma, ganglioneur-
oblastoma or neuroblastoma, and with other tumours
such as adrenal cortical adenoma, spindle cell sar-
coma127 or neuroendocrine carcinoma.128 Hyperplasia
of the adjacent adrenal medulla can be an indication of
MEN-2 syndromes, but it is diﬃcult to identify and
genetic screening is more accurate.129
Immunohistochemical profile
PPGL express the neuroendocrine markers chromogra-
nin, synaptophysin and neurone-speciﬁc enolase. They
may express HMB45 (due to a close histogenic link
with melanocytes130) and more rarely cytokeratins
and vimentin. S-100 highlights the sustentacular cells.
Behaviour
The WHO states that malignancy is deﬁned only by the
presence of metastasis to sites where paraganglial tissue is
not normally found.2 While speciﬁc, this is not sensitive
and is not helpful in predicting tumour behaviour or the
need for close patient follow-up in cases where metastasis
is not identiﬁed. There are no absolute histological criteria
to predict malignancy, and multifactorial approaches
have been suggested. The PASS (Phaeochromocytoma
of the Adrenal gland Scoring Scale) system is summarized
in Table 5.131 All tumours that metastasized were
reported to have scores54. Others have reported signiﬁ-
cant interobserver and intraobserver variations in the use
of the PASS system132 and a more recent paper
proposed an alternative system called the GAPP score
(Grading system for Adrenal Phaeochromocytoma and
Paraganglioma) which is summarized in Table 6.133 This
subdivides the tumours into well-diﬀerentiated (0–2
points), moderately diﬀerentiated (3–6 points) and
poorly diﬀerentiated (7–10 points). It requires further val-
idation to assess its reproducibility and ability to predict
malignant behaviour. Current UK national guidance sug-
gests that these scoring systems are not suﬃciently robust
to be mandated as part of routine reports.134
Figure 1. Pathological features observed in phaeochromocytoma. (a) Enlarged adrenal gland; (b) nested pattern (haematoxylin and
eosin staining); (c) nuclear pleomorphism (haematoxylin and eosin staining staining); (d) sustentacular cells demonstrated by
immunocytochemistry for S-100 protein.
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Follow-up
Guidance on the long-term follow-up of patients oper-
ated on for PPGL has been published by the European
Society of Endocrinology.135 In brief, this guidance rec-
ommends patients should be followed-up annually for
10 years to screen for local or metastatic recurrence or
new tumours, unless they are high risk (i.e. young
patient or those with genetic disease). If this is the
case, patients should be followed annually for life.
From a biochemical perspective, it is proposed that
PMets or UMets are measured two to six weeks post-
operation in patients with elevated MAs preoperatively,
and then annually to screen for local or metastatic
recurrence or new tumours. If PMets or UMets
remain elevated postoperatively, imaging should also
be performed within three months following surgery.
In addition, it is proposed that plasma
chromogranin A is measured preoperatively in patients
with normal PMets or UMets (including 3-MT) and
postoperatively when chromogranin A is raised
preoperatively.
In biochemically inactive PPGL, imaging should be
considered every one to two years to screen for local or
metastatic recurrence or new tumours.
Genetic testing should be considered in all patients
with histologically proven PPGL because over one-
third of patients with PPGL have mutations in the sus-
ceptibility genes, and the presence of mutations
has implications for the patient and family members.
The extent of genetic testing is inﬂuenced by a number
of factors including cost and the diagnostic algorithm
employed for genetic testing.83
Conclusion
PPGL is a rare disease but with signiﬁcant clinical con-
sequences. Advances in the biochemical diagnosis, gen-
etic assessment and screening have seen signiﬁcant
developments in recent years. While surgical treatment
is curative in many cases, the treatment of malignant
disease remains a challenge.
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Table 6. Grading system for Adrenal Phaeochromocytoma and
Paraganglioma.
Parameters Points scored
Histological pattern
Zellballen 0
Large and irregular cell nest 1
Pseudorosette (even focal) 1
Cellularity
Low (<150 cells/10 m2) 0
Moderate (150–250 cells/10 m2) 1
High (more than 250 cells/10 m2) 2
Comedo necrosis
Absence 0
Presence 2
Vascular or capsular invasion
Absence 0
Presence 1
Ki67 labelling index (per cent)
<1 0
1–3 1
>3 2
Catecholamine type
Adrenaline type 0
Noradrenaline type 1
Non-functioning type 0
Total maximum score 10
10 m2: number of tumour cells in a square of a 10m observed under
high power magnification (400).
Table 5. Phaeochromocytoma of the Adrenal gland Scoring
Scale.
Histological feature Score
Large nests of cells or diffuse
growth >10% of tumour
volume
2
Necrosis (confluent or central in
large cell nests)
2
High cellularity 2
Cellular monotony 2
Presence of spindle-shaped
tumour cells (even focal)
2
Mitotic figures (>3 per 10 high
power fields)
2
Extension of tumour into adja-
cent fat
2
Vascular invasion 1
Capsular invasion 1
Profound nuclear pleomorphism 1
Nuclear hyperchromasia 1
Total possible score 20
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